Eagle Soars As It Looks To 13-Year Head Start On Vasopressin In US

FDA Approves Eagle’s Vasostrict ANDA Product; Won Patent Trial In August

 
• By Dean Rudge
  
sales surge
Eagle is in line for a massive cash boost in 2022 • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Products

More from Generics Bulletin